The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition

Neuroscience Letters

Volumn 222, Issue 1, 1997, Pages 61-64

  Rasmussen, Kurt ^a   Gates, Mary R ^b   Burger, James E ^b   Czachura, Janet F ^a  

^a ELI LILLY AND COMPANY   (United States)

^b BUTLER UNIVERSITY   (United States)

Author keywords

Acoustic startle; Antipsychotics; Apomorphine; Cholecystokinin; LY288513; Olanzapine; Schizophrenia

Indexed keywords

APOMORPHINE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; NEUROLEPTIC AGENT; OLANZAPINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; STARTLE REFLEX;

ACOUSTIC STIMULATION; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HORMONE ANTAGONISTS; MALE; PIRENZEPINE; PYRAZOLES; RATS; STARTLE REACTION;

EID: 0031030247     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(97)13346-8     Document Type: Article

References (22)

1. Bakshi, V.P. and Geyer, M.A., Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine, Psychopharmacology, 122 (1995) 198-201.
2. Beasley, C.M., Tollefson, G.D., Sanger, T. and Tran, P., Holman, S. and the North American Olanzapine Study Group, Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial, Neuropsychopharmacology, 14 (1996) 111-123.
3. Bymaster, F.P., Calligaro, D.O., Falcone, J.F., Marsh, R.D., Moore, N.D., Tye, N.C., Seeman, P. and Wong, D.T., Radioreceptor binding profile of the atypical antipsychotic olanzapine, Neuropsychopharmacology, 14 (1995) 87-96.
4. Bymaster, F.P., Perry, K.W., Hemrick-Luecke, S.K. and Fuller, R.W., Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin alphal-adrenergic and muscarinic receptors in vivo in rats, Psychopharmacology, 124 (1996) 87-94.
5. Fuller, R.W. and Snoddy, H.D., Central dopamine receptors mediating pergolide-induced elevation of serum corticosterone in rats: characterization by the use of antagonists, Neuropharmacology, 23 (1984) 1389-1394.
6. Fuller, R.W. and Snoddy, H.D., Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate, Res. Commun. Chem. Pathol. Pharmacol., 77 (1992) 87-93.
7. Geyer, M.A., Swerdlow, N.R., Mansbach, R.S. and Braff, D.L., Startle response models of sensorimotor gating and habituation deficits in schizophrenia, Brain Res. Bull., 25 (1990) 485-498.
8. Helton, D.R., Berger, J.E., Czachura, J.F., Rasmussen, K. and Kallman, M.J., Central nervous system characterization of the new cholecystokinin-B antagonist LY288513, Pharmacol. Biochem. Behav., 53 (1996) 493-502.
9. Hoffman, H.S. and Searle, J.L., Acoustic and temporal factors in the evocation of startle, J. Acoust. Soc. Am., 43 (1968) 269-282.
10. Kehne, J.H., Padich, R.A., McClosky, T.C., Taylor, V.L. and Schmidt, C.J., 5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light pre-pulse inhibition in Wistar rats, Psychopharmacology, 124 (1996) 95-106.
11. Mansbach, R.S., Geyer, M.A. and Braff, D.L., Dopaminergic stimulation disrupts sensorimotor gating in the rat, Psychopharmacology, 94 (1988) 507-514.
12. Moore, N.A., Tye, N.C., Axton, M.S. and Risius, F.C., The behavioral pharmacology of olanzapine, a novel atypical antipsychotic agent, J. Pharmacol. Exp. Ther., 262 (1992) 545-551.
13. Li, D., Simmons, R.M., Howbert, J.J., Rasmussen, K. and Iyengar, S., CCK-B receptors tonically modulate dopaminergic neurons selectively: neurochemical evaluation of LY288513, Soc. Neurosci. Abstr., 19 (1993) 1547.
14. Rasmussen, K., Stockton, M.E., Czachura, J.F. and Howbert, J.J., Cholecystokinin (CCK) and schizophrenia: the selective CCK-B antagonist LY262691 decreases midbrain dopamine unit activity, Eur. J. Pharmacol., 209 (1991) 135-138.
15. Rasmussen, K., Czachura, J.F., Stockton, M.E. and Howbert, J.J., Electrophysiological effects of diphenylpyrazolidinone CCK-B and CCK-A antagonists on midbrain dopamine neurons, J. Pharmacol. Exp. Ther., 264 (1993) 480-488.
16. Rasmussen, K., Howbert, J.J. and Stockton, M.E., Inhibition of A9 and A10 dopamine cells by the cholecystokinin-B antagonist LY262691: mediation through feedback pathways from forebrain sites, Synapse, 15 (1993) 95-103.
17. Rasmussen, K., Yu, M.J. and Czachura, J.F., Quinazolinone cholecystokinin (CCK)-B antagonists decrease midbrain dopamine unit activity, Synapse, 17 (1994) 278-282.
18. Rigdon, G.C. and Viik, K., Prepulse inhibition as a screening test for potential antipsychotics, Drug Dev. Res., 23 (1991) 91-99.
19. Sipes, T.A. and Geyer, M.A., Multiple serotonin receptor subtypes modulate prepulse inhibition of the startle response in rats, Neuropharmacology, 33 (1994) 441-448.
20. Stockton, M.S. and Rasmussen, K., Olanzapine, a novel atypical antipsychotic, reverses D-amphetamine-induced inhibition of midbrain dopamine cells, Psychopharmacology, 124 (1996) 50-56.
21. Swerdlow, N.R., Keith, V.A., Braff, D.L. and Geyer, M.A., Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat, J. Pharmacol. Exp. Ther., 256 (1991) 530-536.
22. Swerdlow, N.R., Braff, D.L., Taaid, N. and Geyer, M.A., Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients, Arch. Gen. Psychiatr., 51 (1994) 139-154.